Geneva, Aug. 17 -- International Clinical Trials Registry received information related to the study (ISRCTN76569516) titled 'A Phase III trial evaluating the response to belimumab after rituximab in lupus patients who have high levels of IgA2 anti-DNA antibodies' on Aug. 10.
Study Type: Interventional
Study Design:
Allocation: Randomized controlled trial
Masking: Blinded (masking used)
Control: Placebo
Assignment: Parallel
Purpose: Treatment
Primary Sponsor: University College London
Condition:
Systemic lupus erythematosus
Skin and Connective Tissue Diseases
Intervention:
Participants will be randomised to receive belimumab or placebo (normal saline, sodium chloride 0.9%) using Sealed Envelope. Intravenous administration of belim...